Antidepressants During Pregnancy: a French Drug Utilisation Study in EFEMERIS Cohort

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 2018 May 28

PMID 29804133

Citations 3

Authors

Caroline Hurault-Delarue

Isabelle Lacroix

Anne Benard-Laribiere

Jean-Louis Montastruc

Antoine Pariente

Christine Damase-Michel

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France.

Methods: We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied.

Results: During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed.

Conclusions: Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.

Citing Articles

The role of prenatal exposure to antidepressants, anxiolytic, and hypnotics and its underlying illness on the risk of miscarriage using BIFAP database.

Kitchin A, Huerta C, Llorente-Garcia A, Martinez D, Ortega P, Cea-Soriano L Pharmacoepidemiol Drug Saf. 2022; 31(8):901-912.

PMID: 35689300 PMC: 9543237. DOI: 10.1002/pds.5488.

The French Pregnancy Cohort: Medication use during pregnancy in the French population.

Berard A, Abbas-Chorfa F, Kassai B, Vial T, Nguyen K, Sheehy O PLoS One. 2019; 14(7):e0219095.

PMID: 31314794 PMC: 6636733. DOI: 10.1371/journal.pone.0219095.

Dispensing patterns of selective serotonin reuptake inhibitors before, during and after pregnancy: a 16-year population-based cohort study from the Netherlands.

Molenaar N, Lambregtse-van den Berg M, Bonsel G Arch Womens Ment Health. 2019; 23(1):71-79.

PMID: 30762147 PMC: 6987060. DOI: 10.1007/s00737-019-0951-5.

References

Bennett H, Einarson A, Taddio A, Koren G, Einarson T . Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004; 103(4):698-709. DOI: 10.1097/01.AOG.0000116689.75396.5f. View

Gavin N, Gaynes B, Lohr K, Meltzer-Brody S, Gartlehner G, Swinson T . Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005; 106(5 Pt 1):1071-83. DOI: 10.1097/01.AOG.0000183597.31630.db. View

Cohen L, Altshuler L, Harlow B, Nonacs R, Newport D, Viguera A . Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006; 295(5):499-507. DOI: 10.1001/jama.295.5.499. View

Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G . Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006; 160(2):173-6. DOI: 10.1001/archpedi.160.2.173. View

Oberlander T, Warburton W, Misri S, Aghajanian J, Hertzman C . Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006; 63(8):898-906. DOI: 10.1001/archpsyc.63.8.898. View

Cooper W, Willy M, Pont S, Ray W . Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007; 196(6):544.e1-5. DOI: 10.1016/j.ajog.2007.01.033. View

Andrade S, Raebel M, Brown J, Lane K, Livingston J, Boudreau D . Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2007; 198(2):194.e1-5. DOI: 10.1016/j.ajog.2007.07.036. View

Lacroix I, Hurault C, Sarramon M, Guitard C, Berrebi A, Grau M . Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009; 65(8):839-46. DOI: 10.1007/s00228-009-0647-2. View

Malm H, Artama M, Gissler M, Ritvanen A . Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011; 118(1):111-120. DOI: 10.1097/AOG.0b013e318220edcc. View

10.

Yonkers K, Gotman N, Smith M, Forray A, Belanger K, Brunetto W . Does antidepressant use attenuate the risk of a major depressive episode in pregnancy?. Epidemiology. 2011; 22(6):848-54. PMC: 3188383. DOI: 10.1097/EDE.0b013e3182306847. View

11.

Hanley G, Oberlander T . The effect of perinatal exposures on the infant: antidepressants and depression. Best Pract Res Clin Obstet Gynaecol. 2013; 28(1):37-48. DOI: 10.1016/j.bpobgyn.2013.09.001. View

12.

Berard A, Sheehy O . The Quebec Pregnancy Cohort--prevalence of medication use during gestation and pregnancy outcomes. PLoS One. 2014; 9(4):e93870. PMC: 3976411. DOI: 10.1371/journal.pone.0093870. View

13.

Wu J, Davis-Ajami M . Antidepressant treatment persistence in low-income, insured pregnant women. J Manag Care Spec Pharm. 2014; 20(6):631-7. PMC: 10437358. DOI: 10.18553/jmcp.2014.20.6.631. View

14.

Huybrechts K, Palmsten K, Avorn J, Cohen L, Holmes L, Franklin J . Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014; 370(25):2397-407. PMC: 4062924. DOI: 10.1056/NEJMoa1312828. View

15.

Jimenez-Solem E . Exposure to antidepressants during pregnancy--prevalences and outcomes. Dan Med J. 2014; 61(9):B4916. View

16.

Charlton R, Jordan S, Pierini A, Garne E, Neville A, Hansen A . Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG. 2014; 122(7):1010-20. DOI: 10.1111/1471-0528.13143. View

17.

Howard L, Molyneaux E, Dennis C, Rochat T, Stein A, Milgrom J . Non-psychotic mental disorders in the perinatal period. Lancet. 2014; 384(9956):1775-88. DOI: 10.1016/S0140-6736(14)61276-9. View

18.

Lupattelli A, Spigset O, Bjornsdottir I, Hameen-Anttila K, Mardby A, Panchaud A . Patterns and factors associated with low adherence to psychotropic medications during pregnancy--a cross-sectional, multinational web-based study. Depress Anxiety. 2015; 32(6):426-36. DOI: 10.1002/da.22352. View

19.

Huybrechts K, Bateman B, Palmsten K, Desai R, Patorno E, Gopalakrishnan C . Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015; 313(21):2142-51. PMC: 4761452. DOI: 10.1001/jama.2015.5605. View

20.

Grzeskowiak L, Morrison J, Henriksen T, Bech B, Obel C, Olsen J . Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG. 2015; 123(12):1919-1928. DOI: 10.1111/1471-0528.13611. View